重组促红细胞生成素治疗正颌患者术后贫血的疗效观察

目的:研究重组促红细胞生成素治疗正颌患者术后贫血的有效性。方法:术中失血500~1200ml正颌患者31例,随机分为2组。治疗组,术后第1天起应用rhEPO 6000IU皮下注射,1周3次,共3次,福乃得(Ferrost sulfatis Etvitamini-medtech)每日1片,共12d;对照组除rhEPO外,其他同治疗组。统计2组患者术中出血量,测定术前及术后第3、7、12天红细胞压积(Hct)和血红蛋白含量(Hb)。结果:术后第12天,治疗组Hb、Hct增加值与对照组Hb、Hct增加值差值比较有显著差异(P<0.05)。结论:rhEPO复合补铁药物,应用于术中出血较多的正颌患者,可有效纠正贫血状态,并可避免因术后贫血而输血。

The effect of recombinant human erythropoietin on postoperative anemia in orthognathic patients

PURPOSE: To observe the effect of rhEPO on postoperative anemia in orthognathic patients. METHODS: 31 patients had 500-1200ml blood loss during orthognathic operation, who were divided into two groups randomly, the experiment group and the control group. The patients in the experiment group received rhEPO 6000IU subcutaneously for 3 times in a week and Ferrost sulfatis Et vitamini-medtech 1 tablet per day via oral administration for 12 days after operation, while the patients in the control group only received the same dose of Ferrost sulfatis Et vitamini-medtech. The loss of blood of the patients during operation were estimated and recorded. Their Hb and Hct were mensured before operation, and in the first, third , seventh, twelfth day after operation. RESULTS: In the twelfth day after operation, the Hb and Hct of the patients in the experiment group had a significantly higher increase than that in the control group (P<0.05).CONCLUSIONS: rhEPO combined Ferrost sulfatis Et vitamini-medtech are suitable to apply in orthognathic patients with anemia after operation, which may effectively accelerate the recovery of their anemia, and avoid transfusion of blood.